-
Mashup Score: 0
In an interview with Targeted Oncology, Douglas Tremblay, MD, discussed the significance of cytoreductive therapy in mitigating thrombotic risk in myeloproliferative neoplasms.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In an interview with Targeted Oncology, Douglas Tremblay, MD, discussed the significance of cytoreductive therapy in mitigating thrombotic risk in myeloproliferative neoplasms.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Douglas Tremblay, MD, discussed the significance of cytoreductive therapy in mitigating thrombotic risk in #MPNs. @IcahnMountSinai @MountSinaiNYC https://t.co/KQ88frTeTj
-
-
Mashup Score: 0Tremblay's Approach to Cytoreduction Across MPNs - 3 month(s) ago
Douglas Tremblay, MD, discusses the factors which influence the decision to recommend cytoreduction for patients with essential thrombocytopenia and polycythemia vera.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Douglas Tremblay, MD, discusses the factors which influence the decision to recommend cytoreduction for patients with #MPNs. @IcahnMountSinai https://t.co/pBocJCKTFm
-
-
Mashup Score: 0Tremblay's Approach to Cytoreduction Across MPNs - 3 month(s) ago
Douglas Tremblay, MD, discusses the factors which influence the decision to recommend cytoreduction for patients with essential thrombocytopenia and polycythemia vera.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: Douglas Tremblay, MD, discusses the factors which influence the decision to recommend cytoreduction for patients with #MPNs. @IcahnMountSinai https://t.co/pBocJCKTFm
-
-
Mashup Score: 0Does the Use of Statins Improve Survival in Essential Thrombocythemia, Polycythemia Vera? - 6 month(s) ago
Home > Polycythemia Vera > Does the Use of Statins Improve Survival in Essential Thrombocythemia, Polycythemia Vera? In patients with polycythemia vera and essential thrombocythemia, statins improved survival and decreased the risk of thrombosis after being diagnosed with myeloproliferative neoplasms (MPNs), according to a study published in Cancer Medicine. “We found that among pa tients with [polycythemia vera] and [essential thrombocythemia], the use of statins improved survival and decreased risk of
Source: www.docwirenews.comCategories: Latest Headlines, Partners & KOLsTweet-
Statins improved survival and decreased thrombosis risk in patients with myeloproliferative neoplasms, according to researchers from @YaleMed. They recommended prescribing statins to high cardiovascular risk patients. https://t.co/xEmmMqMGlU #HemeToday #MPNs #Hematology https://t.co/U0jaIw9j2d
-
-
Mashup Score: 1
Kim Noonan, DNP, ANP-BC, AOCN, FAAN, discusses how nurses can help patients with myeloproliferative neoplasms prevent cardiovascular and thrombotic events.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Kim Noonan, DNP, ANP-BC, AOCN, FAAN, discusses how nurses can help patients with myeloproliferative neoplasms prevent cardiovascular and thrombotic events. #oncology #nursing #MPNs #oncologynurse https://t.co/Xik65FerNg
-
-
Mashup Score: 0
Kim Noonan, DNP, ANP-BC, AOCN, FAAN, discusses how nurses can help patients with myeloproliferative neoplasms prevent cardiovascular and thrombotic events.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nurses Hone In on Cardiovascular and Thrombotic Risks for Patients with MPNs #oncology #nursing #MPNs #oncologynurse https://t.co/Xik65FerNg
-
-
Mashup Score: 0Myeloproliferative Neoplasms: WHO/ICC Systems - [2023 SLIDES] - 7 month(s) ago
By: Allen Wilbanks Date: September 27, 2023 Myeloproliferative neoplasms (MPNs) are a group of blood disorders characterized by the overproduction of blood cells in the bone marrow. Andrew Kuykendall, MD, a well-known hematopathologist and engaging speaker, recently addressed the topic of WHO versus ICC and the…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🩸 Myeloproliferative Neoplasms: Comparing WHO and ICC Classification Systems 📊 @KuykendallMd dives into the world of #MPNs. His unique perspective on "WHO vs. ICC" sheds light on vital implications. 🧬 [video]: https://t.co/21jRWrbQsP @Ryan_Fitzpatric @_MDEducation https://t.co/BsLeZVEPDK
-
-
Mashup Score: 0Current and Emerging Therapies – MPN Research Foundation - 7 month(s) ago
Philadelphia-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are hematologic malignancies characterized by the abnormal proliferation of blood cells in the bone marrow. MPNs cause significant morbidity in the form of burdensome symptoms, potentially fatal cardiovascular complications, progression to…
Source: www.mpnresearchfoundation.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
There are more and better options to treat #MPNs than ever, and many potential new treatments in late-stage clinical trials. Read a treatment landscape summary HERE: https://t.co/e8FL9zWPOl #BCAM #ThisIsBloodCancer @RaajitRampal @GhaithAbuZeinah @MSKCancerCenter @WCMLeukemia https://t.co/Z08JCe9V26
-
-
Mashup Score: 0Momelotinib Receives FDA Approval for Myelofibrosis With Anemia - 7 month(s) ago
Patients with myelofibrosis and anemia can now receive treatment with momelotinib following the agent’s approval by the FDA based on results from the phase 3 MOMENTUM trial.
Source: www.cancernetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with myelofibrosis and anemia can now receive treatment with momelotinib following the agent’s approval by the FDA based on results from the phase 3 MOMENTUM trial. #MPNs | @mpdrc @US_FDA @FDAOncology https://t.co/TQeIDGSaIh
-
Douglas Tremblay, MD, discussed the significance of cytoreductive therapy in mitigating thrombotic risk in #MPNs. @IcahnMountSinai @MountSinaiNYC https://t.co/KQ88frTeTj